Alliancebernstein L.P. Alaunos Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$278 Billion
Q2 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $87,559 - $264,814	-213,560 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.62 - $1.17 $434 - $819	700 Added 0.33%	213,560 $139,000
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $18,421 - $31,941	-16,900 Reduced 7.36%	212,860 $232,000
Q3 2021 Nov 10, 2021	SELL	$1.44 - $2.73 $15,073 - $28,577	-10,468 Reduced 4.36%	229,760 $418,000
Q2 2021 Jul 30, 2021	BUY	$2.63 - $3.67 $59,175 - $82,575	22,500 Added 10.33%	240,228 $634,000
Q1 2021 May 06, 2021	BUY	$2.82 - $5.6 $114,774 - $227,920	40,700 Added 22.99%	217,728 $784,000
Q4 2020 Feb 08, 2021	SELL	$2.09 - $3.09 $63,744 - $94,245	-30,500 Reduced 14.7%	177,028 $446,000
Q3 2020 Nov 12, 2020	SELL	$2.39 - $3.43 $30,114 - $43,218	-12,600 Reduced 5.72%	207,528 $523,000
Q2 2020 Aug 13, 2020	BUY	$2.2 - $3.71 $18,920 - $31,906	8,600 Added 4.07%	220,128 $722,000
Q1 2020 May 14, 2020	SELL	$1.9 - $4.98 $19,250 - $50,457	-10,132 Reduced 4.57%	211,528 $518,000
Q4 2019 Feb 18, 2020	SELL	$3.95 - $5.35 $46,215 - $62,594	-11,700 Reduced 5.01%	221,660 $1.05 Million
Q2 2019 Aug 14, 2019	SELL	$3.98 - $6.2 $16,047 - $24,998	-4,032 Reduced 1.7%	233,360 $1.36 Million
Q1 2019 May 14, 2019	SELL	$2.0 - $4.4 $79,158 - $174,147	-39,579 Reduced 14.29%	237,392 $914,000
Q4 2018 Feb 13, 2019	SELL	$1.61 - $3.62 $1,382 - $3,109	-859 Reduced 0.31%	276,971 $518,000
Q3 2018 Nov 08, 2018	BUY	$2.26 - $3.27 $98,560 - $142,607	43,611 Added 18.62%	277,830 $889,000
Q2 2018 Aug 13, 2018	BUY	$3.02 - $4.94 $119,894 - $196,118	39,700 Added 20.41%	234,219 $707,000
Q3 2017 Nov 13, 2017	BUY	$4.99 - $6.57 $970,649 - $1.28 Million	194,519	194,519 $1.19 Million

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account